Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to improve the way urinary tract infections (UTIs) are tested for antibiotic resistance. The main questions it aims to answer are:
Participants in this study will not be receiving treatments. The study will involve:
Using statistical methods to predict UTI test results based on patient data. Evaluating whether this new approach can provide doctors with more timely and useful information for treating UTIs.
Assessing whether it can help save money and resources in the lab and pharmacy.
The aim of this study is to develop and evaluate an adaptive informatics approach for laboratory antimicrobial susceptibility testing (AST) for urinary tract infection (UTI) pathogens compared with current practice to improve patient outcomes, reduce AMR risks and reduce waste of laboratory resources.
UTI is a leading cause of community and hospital acquired infection and a major driver of antimicrobial prescribing in primary and secondary care. The continued proliferation of AMR also increasingly limits treatment choices for many UTIs. Despite the importance of UTI, antimicrobial susceptibility testing (AST) of urine specimens is based on inflexible 'one-size-fits' all standard operating procedures (SOPs). Either a very large unfocused panel of antimicrobials is immediately tested (leading to wasted resources), or more commonly, and particularly in low or middle income (LMIC) settings, a selected subset of antimicrobials is tested at day one prior to a second or even third panel of antimicrobials. Such an approach does not adapt to prior information such as previous resistance patterns, antimicrobial prescribing, or demographic information, despite these factors being powerful (strong) predictors of resistance. This results in imprecise, inefficient, and inequitable provision of antimicrobial susceptibility information, which provides suboptimal support of decisions for treatment of UTI.
This project will use statistical techniques based on Bayesian causal inference to predict urine AST results and prioritise testing using patient demographics, prescribing, admission, and microbiology laboratory care data. The clinical utility of resulting algorithms will be evaluated in terms of their ability to increase the number, timeliness and appropriateness of usable AST results available to clinicians, and their ability to reduce laboratory resource costs through better test prioritisation. The anticipated benefits of a successfully developed, evaluated, and implemented system are faster and more precise treatments of UTI in patients with drug-resistant organisms and more efficient resource management, particularly in laboratory and pharmacy workflows.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The overall number of susceptible results per panel available at day 1 | The overall number of susceptible results per panel available at day 1 | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| The number of susceptible results per panel available for WHO AWaRe Access category agents at day 1 | The number of susceptible results per panel available for WHO AWaRe Access category agents at day 1 | 2 years |
| The number of susceptible results per panel for orally-administrable agents available at day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with a suspected Urinary Tract Infection
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Liverpool University Hospitals NHS Foundation Trust | Liverpool | North West | United Kingdom |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_ICF | Yes | No | Yes | Study Protocol and Informed Consent Form | Oct 3, 2023 | Nov 16, 2023 | Prot_ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
The number of susceptible results per panel for orally-administrable agents available at day 1 |
| 2 years |
| The number of susceptible results per panel for intravenously-administrable agents available at day 1 | The number of susceptible results per panel for intravenously-administrable agents available at day 1 | 2 years |
| The proportion of panels with no results available for WHO AWaRe Access category agents at day 1 | The proportion of panels with no results available for WHO AWaRe Access category agents at day 1 | 2 years |
| The proportion of panels with no susceptible results of any kind available at day 1 | The proportion of panels with no susceptible results of any kind available at day 1 | 2 years |
| The proportion of WHO Access agent susceptible results for the agent with the highest utility value | The proportion of WHO Access agent susceptible results for the agent with the highest utility value | 2 years |
| The proportion of susceptible results of any kind for the agent with the highest utility value | The proportion of susceptible results of any kind for the agent with the highest utility value | 2 years |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |